Chengdu Biostar Pharmaceuticals

Biostar Pharmaceuticals is a commercial-stage biopharmaceutical company headquartered in Chengdu, China, focused on the discovery and development of innovative oncology therapies. The company specializes in utilizing a proprietary combinatorial biosynthesis platform to develop polyketide-based drugs, specifically epothilone analogs. Its lead product, Utidelone (UTD1), is a genetically engineered epothilone that has been approved by the NMPA in China for the treatment of metastatic breast cancer. Biostar is actively expanding its pipeline with oral formulations of Utidelone and exploring new indications including lung cancer and brain metastases. The company aims to address unmet medical needs in cancer treatment by providing highly effective small molecule drugs with improved safety profiles.